Obermatt
See Similar Stocks →

Immuneering

NMQ:IMRX · US45254E1073
BiotechnologySmall

360° View

no current rank
Price/Sales—
Price/Earnings37
Price/Book62
Dividend Yield—
Revenue Growth—
Profit Growth64
Capital Growth51
TSR 52w80
Leverage64
Liquidity12
Refinancing91
Combined—
Analyst Opinions29
Pro Holdings39
Opinion Changes50
Market Pulse25

Profile

CountryUSA
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeNASDAQGM
Founded2008
Employees54
Websiteimmuneering.com
ISINUS45254E1073
Last UpdateApr 2, 2026
Index & Theme
Machine LearningArtificial IntelligenceOncologyBiotechnologyMedicalPharmaceutical

Description

Immuneering Corporation operates as a clinical-stage oncology company seeking to develop and commercialize tolerated therapies for cancer patients. The company intends to achieve this goal through Deep Cyclic Inhibition of clinically-validated core…

Similar Stocks

The companies this stock is ranked against.

Compare Immuneering with its peers
Acrivon Therapeutics
NMQ:ACRV
6
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Oric Pharmaceuticals
NSQ:ORIC
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Biomea Fusion
NSQ:BMEA
9
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Vaxcyte
NSQ:PCVX
54
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Black Diamond Therapeutics
NSQ:BDTX
21
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
BridgeBio Oncology Therapeutics
NMQ:BBOT
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →